SecBot SecBot
PRESS-RELEASE ·Filed Mar 5, 2026

PROF

Profound Medical Corp.
MIXED
Impact 6/10
Horizonweeks Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

Revenue growth and expanding installed base are positive, but profitability remains distant. Watch for CAPTAIN trial data at EAU Congress (March 13) as a key catalyst. The stock may react positively to clinical validation, but sustained execution and margin improvement will be needed for long-term upside.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$5.31
T+0 close · Mar 5, 2026 · via day close
Latest settled
+25.61%
T+60 · $6.67
Vs SPY
+12.83%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 6 $5.31entry
  2. T+1 · 8mo ago −1.51%α −2.35% · $5.23
  3. T+5 · 8mo ago +3.77%α +5.29% · $5.51
  4. T+20 · 8mo ago +23.54%α +25.58% · $6.56
  5. T+60 · 6mo ago +25.61%α +12.83% · $6.67
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Profound Medical reported record Q4 and full-year 2025 results, with Q4 revenue up 43% YoY to $6.0 million, driven by strong capital equipment sales and recurring revenue. The company strengthened its balance sheet with a $42.45 million equity raise, expanded globally through new distribution deals, and launched AI-enhanced TULSA-AI for BPH. Despite revenue growth, net losses widened to $8.2M in Q4 and $42.6M for the year due to rising operating expenses.

Key Financial Metrics

Revenue
$16.1M
+50.5% YoY
EPS
$-1.41

Key Facts

  • Q4 2025 revenue: $6.0 million, up 43% YoY ($4.2M in Q4 2024)
  • Full-year 2025 revenue: $16.1 million vs. $10.7 million in 2024
  • Gross margin: 67% in Q4 2025 (down from 71% YoY), 71% for full-year 2025 (up from 66%)
  • Net loss: $8.2 million in Q4 2025 vs. $4.9 million in Q4 2024; $42.6 million for FY2025 vs. $27.8 million in FY2024
  • Cash balance: $59.7 million as of Dec 31, 2025, after $36.0M US registered direct and $6.45M Canadian private placement
  • TULSA-PRO installed base: 78 systems as of Dec 31, 2025; guidance for ~120 by end of 2026
  • Launched TULSA-AI Volume Reduction module for BPH, aiming to triple total addressable market to ~600,000 patients annually
  • Frank Baylis appointed to Board; successor to Kris Shah

Financial Impact

Revenue grew 50.5% in 2025 to $16.1M, but net loss increased by $14.8M. Operating expenses rose 31% to $52.6M. Positive cash flow from financing ($41.1M) offset operating cash burn ($38.2M).

revenuegross_marginoperating_expensesnet_losscash_flowdilution

Risk Factors

  • Widening net losses despite revenue growth indicate high cost structure
  • Dependence on capital equipment sales creates revenue volatility
  • Future profitability hinges on scaling recurring revenue and controlling OpEx

Market Snapshot

Exchange
Nasdaq

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3250672

US Market Status

Market Closed · Opens Wed (9h 59m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 5, 2026